NCT01466608View on ClinicalTrials.gov

Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hypercholesterolemia
Interventions
DRUG

Rosuvastatin

Oral administration of rosuvastatin 20 mg once daily for 21 days.

Trial Locations (1)

110-799

Clinical Trials Center, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01466608 - Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients | Biotech Hunter | Biotech Hunter